.jpg)
.png)
Lung
Breast
Gastric
Nasopharyngeal.jpg)
.png)
.png)
.png)
.png)
| Pipeline | Profile | Target | Indication/ Potential indication |
Rights | Stage
Pre-clinical |
Phase 1 |
Phase 2 |
Phase 3 |
NDA |
Country/region where the product is launched |
|---|---|---|---|---|---|---|---|---|---|---|
| RMX3001 (Liporaxel) |
Microtubule StabilizerIt is the 1st oral paclitaxel developed globally. Its safety and ease of administration are expected to bring significant improvements to cancer patients. Based on the unique innovative process technology, it is absorbed through the gastrointestinal tract, thus avoiding premedication, and reducing side effects such as peripheral neuropathy. |
NA | Gastric Cancer | China | Approved in Korea | |||||
| Breast Cancer | China | |||||||||
| ON101 |
TCMReduce wound inflammation Increase epithelialization of epidermal tissues Promote collagen production Reduce formation of wound granulation tissues |
NA | Diabetic Foot Ulcer | Mainland, China | Taiwan, China | |||||
| Lucitanib |
Oral small molecule TKI targeting FGFR1-3, VEGFR1-3, PDGFR α/β, with significant efficacy and high safety Rapid oral absorption, with little food effects on PK Pivotal Phase II study ongoing in multiple sites nationwide for the treatment of various types of tumors Explore combinations with PD-1/PD-L1 antibody |
FGFR1-3 | Thymic Cancer | Mainland, China | Pivotal Phase 2 | |||||
| VEGFR1-3 | Nasopharyngeal Carcinoma | Mainland, China | in Combination with PD-1 | Pivotal Phase 2, in combination with PD-1 | ||||||
| PDGFR α/β | Small Cell Lung Cancer | Mainland, China | n combination with chemothin combination with chemotherapyerapy | |||||||
| Glumetinib |
Clinical development strategy guided by unique biomarkers High selectivity to c-Met and long half-life Multiple studies ongoing in China/Japan/US; preliminary clinical efficacy hasbeen observed, with good safety |
c-Met | c-Met in Non-small Cell Lung Cancer | Global | ||||||
| Exon-14 Skipping in Non-small Cell Lung Cancer | Global | Pivotal Phase 2(China / Japan / US) | ||||||||
| c-Met Mutation in Non-small Cell Lung Cancer | Global | in combination with PD-1 in combination with EGFR inhibitor (Asia) | ||||||||
| CYH33 |
Highly active PI3Kα inhibitor Clinical development strategy guided by unique biomarkers Significant in vivo/vitro anti-tumor effects Preferable safety profile with little and reversible glycemia effects |
PI3Kα | Oncology | Global |
| Profile |
Microtubule StabilizerIt is the 1st oral paclitaxel developed globally. Its safety and ease of administration are expected to bring significant improvements to cancer patients. Based on the unique innovative process technology, it is absorbed through the gastrointestinal tract, thus avoiding premedication, and reducing side effects such as peripheral neuropathy. |
| Target |
N/A |
| Indication/ Potential indication |
Gastric Cancer
Breast Cancer
|
Country / region where the product is launchedApproved in Korea |
|
| 特性 |
中藥降低傷口發炎反應、增加表皮組織上皮化、促進膠原蛋白生成、減少傷口肉芽組織生成 |
| 靶點 |
N/A |
| 適應癥 及潛在 適應癥 |
糖尿病足潰瘍
|
| 特性 |
療效顯著，安全性高的多靶點口服小分子激酶抑制劑；口服給藥吸收快，食物對藥代動力學的影響不顯著；關鍵性II期臨床試驗正在全國多家中心開展，涵蓋多瘤種；正在開展包括PD-1/ PD-L1抗體在內的多種聯合治療探索 |
| 靶點 |
FGFR1-3 |
| 適應癥 及潛在 適應癥 |
胸腺癌
|
| 靶點 |
VEGFR1-3 |
| 適應癥 及潛在 適應癥 |
鼻咽癌
|
| 靶點 |
PDGFR α/β |
| 適應癥 及潛在 適應癥 |
小細胞肺癌
|
| 特性 |
獨特生物標記物指導臨床開發；對c-Met選擇性高，半衰期長；多項臨床試驗在中國/日本/美國進行 |
| 靶點 |
c-Met |
| 適應癥 及潛在 適應癥 |
c-Met非小細胞肺癌
Exon-14跳躍非小細胞肺癌
c-Met變異非小細胞肺癌
|
| 特性 |
活性顯著的高選擇性PI3Kα抑制劑；獨特生物標志物指導臨床開發；顯著的體內/外抗腫瘤作用；藥物安全可控，對血糖影響小且可逆 |
| 靶點 |
PI3Kα |
| 適應癥 及潛在 適應癥 |
腫瘤
|
